Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

51
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
51
Endocarditis IV: Nursing Management01:29

Endocarditis IV: Nursing Management

92
Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
92
Endocarditis I: Introduction01:25

Endocarditis I: Introduction

75
Introduction:Endocarditis is the infection of the endocardium, the inner lining of the heart and its valves. When the heart muscle is involved, the condition is termed myocarditis, while an infection of the outer lining is called pericarditis. Infective endocarditis (IE) primarily affects the endocardium, where pathogens adhere to the valves or lining, forming vegetation that can lead to severe complications. Infective endocarditis occurs when microorganisms, usually bacteria from other body...
75
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

32
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
32
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

49
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
49
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

65
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
65

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolution of resistance patterns in Enterobacterales according to urinary tract infection diagnosis: implications for empirical therapy in a French emergency department.

BMC infectious diseases·2026
Same author

New French Guidelines on Subcutaneous Antibiotic Therapy: A Response to Di Bella et al.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Thoracic infective native aortic aneurysm and T9-T10 spondylodiscitis complicating recurrent Salmonella enterica bacteremia in a 95-year-old: a case report.

Journal of medical case reports·2026
Same author

Subcutaneous antibiotic therapy: Guidelines for clinical practice - Société de Pathologie Infectieuse de Langue Française/Société Française de Gériatrie et de Gérontologie.

Infectious diseases now·2025
Same author

Differences in prescription for impetigo and cellulitis across years in three European countries.

The Journal of antimicrobial chemotherapy·2025
Same author

Prevention and management of syphilis in pregnant and perinatal women.

Infectious diseases now·2025

Related Experiment Video

Updated: Oct 21, 2025

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.6K

Streptococcal and enterococcal endocarditis: time for individualized antibiotherapy?

Clara Flateau1, Adélie Riazi2, Bruno Cassard2

  • 1Department of Tropical and Infectious Diseases, Groupe Hospitalier Sud Ile de France (GHSIF), Melun, France.

The Journal of Antimicrobial Chemotherapy
|September 6, 2021
PubMed
Summary

Current endocarditis treatment doses may cause adverse events. Optimizing beta-lactam concentrations in heart vegetations could personalize antibiotic therapy and enable safe oral transitions.

More Related Videos

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat

Published on: June 4, 2012

16.3K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.1K

Related Experiment Videos

Last Updated: Oct 21, 2025

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.6K
Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat

Published on: June 4, 2012

16.3K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.1K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Cardiology

Background:

  • Current treatment guidelines for streptococcal and enterococcal endocarditis rely on outdated efficacy data.
  • Standard starting doses for beta-lactam antibiotics in endocarditis have not been reassessed and are linked to significant adverse events.

Purpose of the Study:

  • To propose a revised therapeutic objective for beta-lactam treatment in endocarditis.
  • To investigate the potential for personalized antibiotic dosing based on bacterial susceptibility and drug penetration into cardiac vegetations.

Main Methods:

  • Review of existing data on serious infections and beta-lactam pharmacokinetics.
  • Analysis of beta-lactam diffusion gradients within cardiac vegetations.
  • Exploration of the relationship between plasma and vegetation antibiotic concentrations.

Main Results:

  • Maintaining beta-lactam concentrations 4-6 times the minimum inhibitory concentration (MIC) against the causative bacteria for 100% of the time within vegetations is suggested as a therapeutic goal.
  • Evidence suggests a concentration gradient of beta-lactams exists within vegetations.
  • The precise ratio of antibiotic concentration between plasma and vegetation at steady state remains undetermined.

Conclusions:

  • Reassessing beta-lactam doses for endocarditis is crucial due to potential adverse events associated with current regimens.
  • Determining the plasma-to-vegetation antibiotic concentration ratio is key to achieving targeted patient-specific dosing.
  • This approach could facilitate personalized antibiotherapy and a safe transition to oral medications.